Navigation Links
Genta Receives NASDAQ Non-Compliance Notice
Date:12/24/2007

trials as a potential treatment for diseases associated with accelerated bone loss. Ganite(R) and Genasense(R) are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:

-- the Company's ability to obtain necessary regulatory approval for

Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

European Medicines Agency ("EMEA");

-- the safety and efficacy of the Company's products or product

candidates;

-- the Company's assessment of its clinical trials;

-- the commencement and completion of clinical trials;

-- the Company's ability to develop, manufacture, license and sell its

products or product candidates;

-- the Company's ability to enter into and successfully execute license

and collaborative agreements, if any;

-- the adequacy of the Company's capital resources and cash flow

projections, and the Company's ability to obtain sufficient financing

to maintain the Company's planned operations;

-- the adequacy of the Company's patents and proprietary rights;

-- the impact of litigation that has been brought against the Company and

its officers and directors and any proposed settlement of such

litigation;

-- the Company's ability to regain compliance with the NASDAQ's listing

qualifications; and

-- the other risks described under Cer
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Syngenta Licenses Chromatin Gene Stacking Technology
3. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
4. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
5. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
6. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
7. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
8. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
9. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
10. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
11. IsoTis Receives FDA Clearance for Accell Family of Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ... July 27, 2015 , ... Brady ... new video: 3 Ways to GHS Labels . This video provides useful ... Harmonized System (GHS) by effectively labeling chemical containers. , “With the fourth and ...
(Date:7/27/2015)... July 27, 2015 Research presented at the ... expand on the studies that led to a fingerprick ... for this disease to receive approval from the World ... breaking Ebola,s grip on West Africa ... enabling healthcare workers to isolate and treat these patients ...
(Date:7/27/2015)... 2015 According to the new Market ... Pre-formulated Media), by Application (Biobanking, Regenerative Medicine, Drug Discovery), by ... , Asia-Pacific , Rest of the ... media market was valued at $247.7 million in 2014, which ... at a CAGR of 18.2% between 2014 and 2019. ...
(Date:7/27/2015)... 2015 Junto Health, a company that helps ... develop new technology solutions, today announced the launch of ... leader in health care policy consulting. Working together with ... collaborative innovation process while, at the same time, they ... policy, health care finance and the delivery of health ...
Breaking Biology Technology:Brady Releases “3 Roads to GHS Labels” Video 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 3Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Junto Health Announces a Unique Partnership with Sachs Policy Group 2Junto Health Announces a Unique Partnership with Sachs Policy Group 3Junto Health Announces a Unique Partnership with Sachs Policy Group 4
... Nektar,Therapeutics (Nasdaq: NKTR ) announced today that ... Markets Focus on Healthcare Conference in New,York at the ... a.m. ET., The presentation and Q&A session will ... posted on the Investor Relations, Events,Calendar section of the ...
... Bionovo, Inc.,(Nasdaq: BNVI ), a leader in the ... of women,s health and cancer, is scheduled to,present at the ... presentation by Tom Chesterman, SVP and CFO of Bionovo, Inc., ... local time at the,Millennium Broadway Hotel in New York City., ...
... 28 RainDance Technologies, Inc.,a developer of ... of Christopher McNary as President and Chief,Executive ... of the,Board, in driving RainDance Technologies, vision ... Laboratory System in the Life,Sciences and other ...
Cached Biology Technology:RainDance Technologies Appoints McNary President and CEO 2RainDance Technologies Appoints McNary President and CEO 3
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
(Date:7/7/2015)... 2015 Research and ... of the "Capacitive Fingerprint Sensors Patent Landscape" ... this date, fingerprint sensing technology is the most ... are well developed. This patent landscape focuses on ... The domain of capacitive fingerprint sensors is closely ...
(Date:7/2/2015)... , June 25, 2015 ... of the "Next Generation Biometrics Market by Application, ... report to their offering. The next ... by 2020, at a CAGR of 17.9% between 2015 ... leading application for the market. Safran SA ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... Plant Industry scientists and international collaborators have discovered the ... epidemic years cost wheat growers worldwide in excess of ... the prestigious journal Science , scientists from CSIRO ... Maize and Wheat Improvement Center have identified a wheat ...
... haematologist Professor Christopher Baum and his colleagues Dr. Ute ... Ursula M. Hndel Animal Welfare Prize. The prize was ... School (Medizinische Hochschule Hannover, MHH) in recognition of their ... gene therapies that significantly reduces the number of animal ...
... children can be expensive, time-consuming for clinicians, and tedious for ... a large number of blood draws. A new calculation eliminates ... that can be performed in a clinical setting to offer ... new estimate formula, developed from a study that will appear ...
Cached Biology News:Saving wheat crops worldwide 2Reducing animal experiments through top-class research 2Reducing animal experiments through top-class research 3Updated formula measures kidney function more accurately 2Updated formula measures kidney function more accurately 3
...
...
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
... is suitable for use with ... incubating with 0.1% diethylpyrocarbonate (DEPC) ... the DEPC.DNase/RNase-Free Distilled WaterDistilled Water ... all molecular biology applications. It ...
Biology Products: